The latest price target for Crinetics Pharmaceuticals (NASDAQ:CRNX) was reported by Wolfe Research on February 4, 2025. The analyst firm set a price target for $0.00 expecting CRNX to fall to within 12 months (a possible -100.00% downside). 37 analyst firms have reported ratings in the last year.

The latest analyst rating for Crinetics Pharmaceuticals (NASDAQ:CRNX) was provided by Wolfe Research, and Crinetics Pharmaceuticals initiated their peer perform rating.

The last upgrade for Crinetics Pharmaceuticals Inc happened on January 22, 2025 when Jefferies raised their price target to $55. Jefferies previously had a hold for Crinetics Pharmaceuticals Inc.

There is no last downgrade for Crinetics Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Crinetics Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Crinetics Pharmaceuticals was filed on February 4, 2025 so you should expect the next rating to be made available sometime around February 4, 2026.

While ratings are subjective and will change, the latest Crinetics Pharmaceuticals (CRNX) rating was a initiated with a price target of $0.00 to $0.00. The current price Crinetics Pharmaceuticals (CRNX) is trading at is $37.46, which is out of the analyst’s predicted range.